Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Non-Current Assets (2016 - 2026)

Lexaria Bioscience's Non-Current Assets history spans 12 years, with the latest figure at $717021.0 for Q1 2026.

  • Quarterly results put Non-Current Assets at $717021.0 for Q1 2026, down 24.77% from a year ago — trailing twelve months through Feb 2026 was $717021.0 (down 24.77% YoY), and the annual figure for FY2025 was $706776.0, down 27.12%.
  • Non-Current Assets for Q1 2026 was $717021.0 at Lexaria Bioscience, up from $687678.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.0 million in Q2 2023 to a low of $687678.0 in Q4 2025.
  • The 5-year median for Non-Current Assets is $925058.0 (2024), against an average of $877517.3.
  • The sharpest move saw Non-Current Assets tumbled 31.29% in 2022, then increased 18.63% in 2023.
  • Year by year, Non-Current Assets stood at $854110.0 in 2022, then increased by 9.25% to $933140.0 in 2023, then rose by 3.74% to $968033.0 in 2024, then decreased by 28.96% to $687678.0 in 2025, then increased by 4.27% to $717021.0 in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $717021.0, $687678.0, and $706776.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.